What question did this study set out to answer?

To comprehensively evaluate the therapeutic effects of resveratrol supplementation on metabolic and inflammatory risk factors in adults with obesity-related non-communicable diseases.

March 1, 2026In VivoOpen Access

Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases

Q: What are the key findings of this study?

Resveratrol supplementation significantly reduced insulin resistance (HOMA-IR), total cholesterol, triglycerides, LDL cholesterol, systolic and diastolic blood pressure, and inflammatory markers (hs-CRP, TNF-α, IL-6) in adults with obesity-related metabolic disorders compared to placebo.

Q: What is the clinical evidence from this study?

Study design: Meta-Analysis. Population: Adults with obesity-related metabolic disorders or associated risk factors including T2DM, NAFLD, metabolic syndrome, and dyslipidemia (n=2551). Intervention: Resveratrol supplementation vs. Placebo or standard care. Primary outcome: Metabolic and inflammatory parameters including HOMA-IR, total cholesterol, triglycerides, LDL cholesterol, systolic and diastolic blood pressure, hs-CRP, TNF-α, IL-6, fasting glucose, fasting insulin, HbA1c, liver enzymes (ALT, AST, GGT) (Standardized mean differences with significant reductions in HOMA-IR, TC, TG, LDL, SBP, DBP, hs-CRP, TNF-α, IL-6 reported, p=p<0.05 for significant outcomes).

Q: What does this research mean for the field?

Resveratrol supplementation significantly reduced insulin resistance (HOMA-IR), total cholesterol, triglycerides, LDL cholesterol, systolic and diastolic blood pressure, and inflammatory markers (hs-CRP, TNF-α, IL-6) in adults with obesity-related metabolic disorders compared to placebo. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

Ask AI

Bookmark

Key result

Resveratrol lowers blood pressure, lipids, insulin resistance, and inflammation vs placebo in obesity-related metabolic disorders.

Standardized mean differences with significant reductions in HOMA-IR, TC, TG, LDL, SBP, DBP, hs-CRP, TNF-α, IL-6 reported
P<0.05 for significant outcomes
n=2,551

Why the study?

Evidence from RCTs on resveratrol is inconsistent and commercial products vary, leaving uncertainty about its true efficacy in obesity-related non-communicable diseases.

Does resveratrol supplementation improve metabolic and inflammatory parameters in adults with obesity-related metabolic disorders?

Key Points

To comprehensively evaluate the therapeutic effects of resveratrol supplementation on metabolic and inflammatory risk factors in adults with obesity-related non-communicable diseases.
Systematic search of PubMed, Embase, Cochrane Library, and Web of Science up to July 2025 following PRISMA 2020 guidelines.
Identified 40 randomized controlled trials enrolling 2,551 adults with obesity-related metabolic disorders or associated risk factors receiving resveratrol versus placebo.
Synthesized outcomes using random-effects models calculating standardized mean differences with 95% confidence intervals and assessed heterogeneity using the I² statistic.
Resveratrol supplementation significantly reduced HOMA-IR, total cholesterol, triglycerides, LDL cholesterol, systolic blood pressure, diastolic blood pressure, hs-CRP, TNF-α, and IL-6.
No consistent significant changes were observed for HDL cholesterol, body weight, BMI, fat mass, waist circumference, hip circumference, AST, ALT, GGT, or liver fat.
Observed effect sizes varied according to intervention dosage and duration, demonstrating selective metabolic and anti-inflammatory activity rather than broad anthropometric changes.

Study Design

Type

Meta-Analysis (n=2,551)

Structured PICO

Does resveratrol supplementation improve metabolic and inflammatory parameters in adults with obesity-related metabolic disorders?

Population

2,551 adults with obesity-related metabolic disorders or associated risk factors pooled from 40 RCTs.

Intervention

Resveratrol supplementation (various doses and durations greater than two weeks).

Comparator

Placebo or standard care control.

Outcome

Systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), fasting insulin, hemoglobin A1c (HbA1c), HOMA-IR, inflammatory markers (TNF-α, hs-CRP, IL-6), liver enzymes (ALT, AST, GGT), and lipid parameters (TC, TG, HDL-C, LDL-C).surrogate

Main Result

Effect estimate: Standardized mean differences with significant reductions in HOMA-IR, TC, TG, LDL, SBP, DBP, hs-CRP, TNF-α, IL-6 reported

p-value: p<0.05 for significant outcomes

Resveratrol supplementation provides modest benefits for specific lipid, glycemic, and inflammatory markers in obesity-related metabolic disorders, but does not broadly improve all risk factors such as body weight or liver fat.

Limitations

Heterogeneity in resveratrol doses and intervention durations among included studies
Inconsistent findings across trials possibly due to variable participant populations and treatment regimens
No broad effects observed across all obesity-related risk factors, especially anthropometric measures and liver fat
Publication bias and risk of bias in some included studies not fully ruled out
Lack of long-term large-scale RCTs to confirm optimal dosing and clinical utility
Effect sizes varied by intervention dose and duration
Lack of large-scale, long-term RCTs to clarify optimal dosing strategies

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Modest, selective benefits in obesity-related metabolic disorders temper expectations for broad improvement; reinforces surrogate marker data but leaves clinical outcomes unproven.

Abstract

Background/Aim: Resveratrol, a polyphenolic compound found in grapes, berries, and peanuts, has been linked to antioxidant, anti-inflammatory, and vasoprotective effects. Yet, evidence from randomized controlled trials (RCTs) remains inconsistent, and the quality, dosage, and cost of commercial resveratrol products vary considerably, raising uncertainty about their true efficacy. A comprehensive synthesis of its effects on obesity-related non-communicable diseases (NCDs) is therefore warranted. Given that obesity is a key driver of metabolic dysregulation underlying diabetes, cardiovascular disease, and fatty liver disease, clarifying resveratrol’s potential in overweight and obese populations is of particular importance. Materials and Methods: We systematically searched PubMed, Embase, the Cochrane Library, and Web of Science for RCTs published up to July 2025 that evaluated resveratrol supplementation in adults with obesity-related metabolic disorders or associated risk factors. Study selection and data extraction followed PRISMA 2020 guidelines. Pooled estimates were calculated using random-effects models, and heterogeneity was assessed with the I² statistic. Results: Forty RCTs involving 2551 participants were included. Resveratrol significantly reduced the homeostatic model assessment of insulin resistance (HOMA-IR), total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL) cholesterol, systolic blood pressure (SBP) and diastolic blood pressure (DBP), high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6). No consistent changes were observed for high-density lipoprotein (HDL) cholesterol, body weight (BW), body mass index (BMI), fat mass, hip circumference (BC), waist circumference (WC), aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), or liver fat. To our knowledge, this meta-analysis includes the largest number of RCTs to date and the most comprehensive coverage of obesity-related metabolic and inflammatory endpoints. Effect sizes varied by intervention dose and duration. Conclusion: Resveratrol supplementation shows modest benefits on selected metabolic and inflammatory parameters but does not exert broad effects across all obesity-related NCD risk factors. Its potential role may be most relevant in populations with metabolic disturbances. Large-scale, long-term RCTs are warranted to clarify optimal dosing strategies and establish its utility in the prevention and management of obesity-related non-communicable diseases.

Figures from the paper

Published by In Vivo · CC BY-NC-ND

Cite This Study

Shen et al. (2026) conducted a meta-analysis in Adults with obesity-related metabolic disorders or associated risk factors including T2DM, NAFLD, metabolic syndrome, and dyslipidemia (n=2,551). Resveratrol supplementation vs. Placebo or standard care was evaluated on Metabolic and inflammatory parameters including HOMA-IR, total cholesterol, triglycerides, LDL cholesterol, systolic and diastolic blood pressure, hs-CRP, TNF-α, IL-6, fasting glucose, fasting insulin, HbA1c, liver enzymes (ALT, AST, GGT) (Standardized mean differences with significant reductions in HOMA-IR, TC, TG, LDL, SBP, DBP, hs-CRP, TNF-α, IL-6 reported, p=p<0.05 for significant outcomes). Resveratrol supplementation significantly reduced insulin resistance (HOMA-IR), total cholesterol, triglycerides, LDL cholesterol, systolic and diastolic blood pressure, and inflammatory markers (hs-CRP, TNF-α, IL-6) in adults with obesity-related metabolic disorders compared to placebo.

synapsesocial.com/papers/69a3d7eeec16d51705d2e5ba https://doi.org/10.21873/invivo.14235

View Full Paper

Ask AI

Bookmark

Implication

Modest, selective benefits in obesity-related metabolic disorders temper expectations for broad improvement; reinforces surrogate marker data but leaves clinical outcomes unproven.

Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases

Key Points

Study Design

Structured PICO

Main Result

Limitations

Discussion

Implication

Abstract

Figures from the paper

Cite This Study

Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases

Key Points

Study Design

Structured PICO

Main Result

Limitations

Discussion

Implication

Abstract

Figures from the paper

Cite This Study

Keep reading

Keep reading